Search
for
Sort by
Research 30 of 142
- FDA approves label addition for PDE-5 inhibitor
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
- Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, and EAU recommendations
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- Udenafil Induces the Hair Growth Effect of Adipose-Derived Stem Cells
- 1194: The Long Term Effects of Doxazosin, Finasteride, and the Combination on Sexual Function in Men Participating in the MTOPS Study
- Impact of Hormones on Female Sexual Function and Dysfunction
- 311 Novel Penile Ultrasound Technique to Explain Mechanism of Erectile Dysfunction (ED) in Young Patients using Finasteride for Androgenic Alopecia
- Wider clinical applications of fumaric acid esters: A useful option in psoriasis patients with multiple sclerosis
- Sexual Medicine Reviews—The Premiere Review Journal for the Field of Sexual Medicine
- The urologic impact of long-term finasteride 1-mg use for androgenic alopecia: a matched-cohort database analysis
- IP28-24 RISK OF ERECTILE DYSFUNCTION AMONG REPRODUCTIVE-AGED MEN FOLLOWING LOW-DOSE FINASTERIDE USE FOR ANDROGENETIC ALOPECIA: A PROPENSITY-MATCHED COHORT STUDY
- MP11-05 THE UROLOGIC IMPACT OF LONG-TERM FINASTERIDE-1 MG USE FOR ANDROGENIC ALOPECIA: A MATCHED-COHORT DATABASE ANALYSIS
- Medical management of benign prostatic hyperplasia
- Study of QuantiFERON’S conversion/reversal phenomena in patients with psoriasis during biological treatment
- The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease
- Faculty Opinions recommendation of Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach.
- Evaluation of risk of SSRI-associated impotence and low libido in men exposed to finasteride
- Risks and side effects in the medical management of benign prostatic hyperplasia
- Organic Causes of Erectile Dysfunction in Men Under 40
- Patient-convenient Long-term Alopecia Treatment via PLGA Microsphere-Loaded Candlelit Microneedle
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- 8 Finasteride-Associated Suicide and Depression in Men Treated for Hypogonadism and Impotence
- Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
- Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
- Management of Recurrent Ischemic Priapism 2014: A Complex Condition with Devastating Consequences